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Abstract
HER2+ early breast cancer is a heterogeneous disease, comprising all the intrinsic breast cancer 
subtypes. The only biomarker available nowadays for anti-HER2 treatment selection is HER2 
status itself, but estrogen receptor (ER) status is emerging as a robust predictive marker within 
HER2+ disease. In this Perspective, we discuss the biological and clinical differences between 
patients with HER2+/ER positive (ER+) disease versus those with HER2+/ER negative (ER-neg) 
tumors, namely short- and long-term (>5 years after diagnosis) prognosis, response to neoadjuvant 
treatment and benefit from adjuvant anti-HER2 targeted therapies. We also address other possible 
biomarkers to be used for patient selection in future clinical trials, like gene signatures, PAM50 
subtypes, tumor-infiltrating lymphocytes, PIK3CA mutations, and changes in Ki67 score during 
treatment and discuss their limitations. Finally, we suggest new clinical trial designs that can have 
an impact on clinical practice, aiming to test treatment de-escalation separately for patients with 
HER2+/ER+ and HER2+/ER-neg tumors. We also propose an integrated classification of HER2+ 
disease, comprising DNA, RNA, protein expression and microenvironment characteristics, in order 
to identify those tumors that are truly “HER2-addicted” and may benefit the most from anti-HER2 
treatment.
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Perspective
It is well-known that HER2+ breast cancer is a heterogeneous disease (1,2). Besides HER2 
status itself, there are no validated biomarkers to identify patients likely to benefit from anti-
HER2 treatments (3). It has been proposed, however, that the expression of the estrogen 
receptor (ER) drives variable degrees of benefit from existing anti-HER2 treatment 
strategies. An increasing number of trials are being developed targeting specifically 
HER2+/ER-positive (ER+) or HER2+/ER-negative (ER-neg) early breast cancer (EBC) and 
we believe that, in the future, these may be regarded as distinct diseases or we may need 
additional tools to identify the varying biology within HER2+ disease that is represented by 
ER status.
Biological differences
Distinct biological characteristics may justify the different clinical behavior observed in 
HER2+ EBC according to ER status. The ER- and the HER2-pathways drive breast cancer 
proliferation by a complex interaction of cellular signaling processes (4). Due to the 
intracellular crosstalk between HER2 and ER, treatments interfering with one of the two 
pathways can have an effect on the other, with reactivation of ER-signaling being a known 
mechanism of resistance to anti-HER2 agents in HER2+/ER+ breast cancer (5).
The distribution of intrinsic (PAM50) breast cancer subtypes within HER2+ tumors also 
differs according to ER status (6): around 75% of HER2+/ER-neg tumors and 30% of 
HER2+/ER+ are “HER2-Enriched”, which is the subtype associated with HER2/EGFR-
pathway activation (2), high proliferation rates, and an immune-activated stroma with 
elevated tumor-infiltrating lymphocytes (TILs) concentrations (Figure 1). On the other hand, 
around 70% of HER2+/ER+ tumors are luminal A/B, which are ER-dependent tumors, with 
low HER2/EGFR-pathway activation and a high rate of PIK3CA mutations (1), that are 
associated with lower response to anti-HER2 treatment (7).
Differences in prognosis between HER2+/ER+ and HER2+/ER-neg EBC in 
the “trastuzumab era”
In the first 5 years after diagnosis, HER2+/ER-neg patients have worse survival compared to 
the HER2+/ER+ group. Among 42,887 patients treated between 2010–2015, 5-year overall 
survival (OS) rates were 88.2% in HER2+/ER+ vs. 83.9% in HER2+/ER-neg subgroup 
(p<0.001) (8). Yet, after 5 years, recurrence risk lowers among HER2+/ER-neg patients, but 
is maintained among those with HER2+/ER+ tumors (9–11). This leads to similar long-term 
prognosis: in the HERA trial, 12-year OS in the trastuzumab arms was 81% in the 
HER2+/ER+ and 78%−79% in the HER2+/ER-neg subgroup (9).
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On the other hand, achievement of a pathological complete response (pCR) after 
neoadjuvant treatment is a prognostic factor in both groups, but it has a stronger impact on 
event-free survival (EFS) in the HER2+/ER-neg (hazard ratio [HR] 0.25) compared to the 
HER2+/ER+ subgroup (HR 0.58) (12). However, overall median follow-up for EFS in this 
meta-analysis was just 5.4 years, thus the prognostic impact of pCR on late recurrences is 
currently unknown.
Is ER status predictive of treatment benefit?
It is well-documented that HER2+/ER-neg patients treated with chemotherapy and dual anti-
HER2 therapy present higher pCR rates (61%−91%) compared to patients with HER2+/ER+ 
EBC (26%−56%) (13–20); and, compared with HER2+/ER+ tumors, HER2+/ER-neg 
tumors have consistently demonstrated greater increases in pCR rates with dual anti-HER2 
therapy plus chemotherapy compared with chemotherapy/trastuzumab alone (13,18–20). 
Nonetheless, duration of anti-HER2 treatment seems to matter in HER2+/ER+ EBC: in 
TBCRC023, increasing treatment length with trastuzumab/lapatinib and letrozole from 12 to 
24 weeks led to an increase in pCR rates from 9% to 33%, whereas no significant difference 
was observed in HER2+/ER-neg tumors (21). This suggests that in HER2+/ER+ tumors, in 
the absence of chemotherapy, prolonged inhibition of the HER2 and ER pathways may be 
necessary not only to decrease proliferation, but to induce apoptosis as well. Yet, adding 
concomitant endocrine therapy (ET) to anti-HER2 therapy and/or chemotherapy did not 
yield any advantage in the NSABP B-52 or ADAPT HER2+/HR+ studies (22,23). This is 
intriguing, as one would expect that the ER/HER2 pathways-blockade would suppress their 
crosstalk and lead to higher tumor response.
On the opposite end of the spectrum, the high chemo-sensitivity of HER2+/ER-neg tumors 
was demonstrated in the ADAPT HER2+/HR- study, in which the addition of paclitaxel to 
trastuzumab/pertuzumab increased pCR rates from 36% to 91% (17). Similarly, the 
KRISTINE trial showed a significantly higher pCR rate in this group with docetaxel/
carboplatin plus trastuzumab/pertuzumab compared to T-DM1/pertuzumab (73% vs. 54%, 
respectively) (16).
In the adjuvant setting, HER2+/ER+ and HER2+/ER-neg subgroups have a similar degree of 
proportional risk reduction with trastuzumab (9,24,25). Yet, in contrast with the neoadjuvant 
setting, duration of adjuvant trastuzumab treatment might matter more for HER2+/ER-neg 
EBC: in a recent meta-analysis, patients receiving 9 weeks to 6 months of trastuzumab had 
worse EFS compared to patients treated for 12 months (26). Therefore, in HER2+/ER-neg 
disease, longer trastuzumab treatment is probably more effective than a shorter course. 
However, the trials included in this meta-analysis had a median follow-up of less than 5 
years, so long-term data on HER2+/ER+ patients are needed.
Challenging this idea, the ExteNET trial showed that sequential anti-HER2 blockade 
(summing two years of treatment) was beneficial for HER2+/ER+ patients, but not for 
HER2+/ER-neg patients (27). On the other hand, updated survival results from APHINITY 
show that early dual HER2-blockade with trastuzumab/pertuzumab has an effect both in 
HER2+/ER-neg and HER2+/ER+ diseases (28). Reasons for this difference may lie in these 
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drugs’ mechanisms of action, timing of administration, and length of follow-up. After 
stopping adjuvant trastuzumab, HER2+/ER+ patients continue ET, but the single-blocking of 
the ER-pathway may lead to re-activation of the HER2-pathway on residual trastuzumab-
resistant malignant cells (4). As neratinib was administered after trastuzumab, it may have 
prevented the re-activation of the HER2-pathway and, hence, benefited HER2+/ER+ 
patients, but not those with HER2+/ER-neg tumors. As neratinib irreversibly inhibits several 
HER-family members (EGFR, HER2, HER4), it may have prevented this cross-talk in a 
more effective way than administration of trastuzumab for 2 years (which only inhibits 
HER2) (9). In APHINITY, the early dual blockade has probably eliminated trastuzumab-
resistant cells in part of the patients, but the benefit was seen later in HER2+/ER+ patients, 
has these tend to have later relapses, as compared to HER2+/ER-neg patients. .
Recently, the KATHERINE trial showed that in patients with residual disease after 
neoadjuvant treatment, 1 year of adjuvant T-DM1 was superior to trastuzumab, 
independently of ER status (29). It should be noted that this trial included selected high-risk 
patients, for whom suboptimal response to neoadjuvant trastuzumab could have influenced 
the benefit from a salvage treatment with a different anti-HER2 drug, potentially 
confounding the effect of baseline ER status.
How can we identify patients who benefit more or less from anti-HER2 
treatment?
The biggest question nowadays is how to select patients for escalation/de-escalation 
approaches, maintaining or increasing pCR rates and survival, with minimal toxicity. 
Therefore, the quest for finding prognostic and predictive biomarkers has been intense (3). 
One attempt was to quantify gene expression levels of ESR1 and ERBB2, showing that high 
levels of ERBB2 (20,30–32) and low levels of ESR1 (31) are associated with higher pCR 
rates. Expression levels of genes involved in HER2- and ER-pathways were also combined 
in a predictive model in an analysis of the NSABP B-31 trial. Patients were classified into 3 
groups: i) “high ESR1”/“low-intermediate ERBB2”: no benefit from trastuzumab (HR 1.58); 
ii) “low ESR1”/“low-intermediate ERBB2”: moderate benefit (HR 0.60); iii) “low-
intermediate ESR1”/“high ERBB2”: large benefit (HR 0.28) (33). This 8-gene signature, 
showing no linear correlation between ERBB2 and ESR1 mRNA levels and benefit from 
adjuvant trastuzumab, was later validated in the N9831 and FB-7 trials (34,35). Nonetheless, 
these intriguing findings have not yet been tested in prospective studies or applied in the 
clinic.
Other biomarker studies focused on the correlation between PAM50 subtypes and benefit 
from anti-HER2 treatment. A consistent finding is that HER2-Enriched tumors present 
higher pCR rates (between 28%−72%) when treated with anti-HER2 therapies (with/without 
chemotherapy), compared to other subtypes (20,32,36,37), showing that HER2-Enriched 
subtype predicts sensitivity to anti-HER2 treatment. In fact, several studies show that ER 
status loses its association with pCR when subtype is taken into account, indicating that 
subtype captures most of the information displayed by ER status and also brings additional 
information (20,32,36,37). One important aspect to take into account when designing de-
Brandão et al. Page 4













escalation trials is that HER2-Enriched subtype is also chemo-sensitive, with overall pCR 
rates in HER2+ disease of around 60% with vs. 30% without chemotherapy, respectively 
(20,32,36,37).
It has also been proposed that high scores of a gene expression-signature of loss-of-function 
of RB1 may identify HER2+ tumors more likely to respond to chemotherapy and this 
concept has been validated in HER2+/ER+ tumors using a refined 87 gene-signature (RBsig) 
(38,39). Moreover, higher TILs levels are associated with improved pCR rates and survival 
both in HER2+/ER-neg and HER2+/ER+ EBC (40,41), and evidence of immune activation 
by RNA-signatures is independently associated with higher pCR (20,31). It has also been 
demonstrated that high TIL levels (>75%) predicted benefit from adjuvant trastuzumab/
pertuzumab vs. trastuzumab alone (42). Of note, TILs levels tend to be lower in HER2+/ER
+ compared to HER2+/ER-neg tumors (40).
A decrease in Ki67 during neoadjuvant treatment is a surrogate for response and prognosis 
in HER2-negative/ER+ EBC, so its role is being evaluated in HER2+/ER+ disease (43). In 
ADAPT HER2+/HR+, patients with an early tumor response (Ki67 decrease≥30% or low-
cellular tumor at 3 weeks) had a higher pCR rate compared to nonresponders (36% vs. 20%, 
respectively) (23). In the PerELISA trial, HER2+/ER+ patients with a Ki67 drop after 2 
weeks of letrozole (molecular responders) continued on letrozole, and trastuzumab/
pertuzumab were added for another 12 weeks. Nonresponders were switched to paclitaxel 
with trastuzumab/pertuzumab. The pCR rate was 21% among molecular responders, but 
even more remarkable was the 81% pCR rate among nonresponders (44). Even though the 
correlation between an early Ki67 drop and long-term survival is not yet validated in patients 
with HER2+ tumors, it could become a biomarker for selecting patients with HER2+/ER+ 
who do not respond to ET and would be candidates to chemotherapy, given the impressive 
pCR rate achieved in this subgroup.
Thus, a dilemma for future clinical trials is how to select patients: should one be guided by 
HER2/ER immunohistochemistry status, by molecular subtype or by a combination of both? 
Based on current evidence, tumors with the highest anti-HER2 sensitivity are those HER2+ 
by immunohistochemistry/ISH and the PAM50 HER2-Enriched. Whether additional 
biomarkers will help identify higher anti-HER2 sensitivity is currently unknown, although 
TILs and PIK3CA mutations arise as promising candidates (Figure 2). Indeed, tumors with 
high HER2 amplification and an intact PI3K pathway are especially sensitive to HER2-
targeted therapies (30). TILs could also potentially be used to select patients, but there are 
no standardized cut-points to define “high” vs. “low” TILs infiltration (45). Another 
question is if an early biopsy to assess Ki67 levels should be performed in HER2+/ER+ 
patients receiving neoadjuvant treatment. This is limited by Ki67 low reproducibility (46) 
and absence of validation as a surrogate for long-term survival benefit in HER2+ EBC.
De-escalating strategies: a plea for separate trials according to ER status
Despite distinct biological and clinical characteristics between HER2+/ER-neg and 
HER2+/ER+ EBC, they are still treated similarly, except for ET. Nevertheless, different de-
escalation strategies for HER2+ EBC might be explored according to ER status: a) to 
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decrease anti-HER2 treatment duration; b) to avoid anthracyclines, and c) to design 
chemotherapy-free regimens.
As detailed before, a meta-analysis showed a worse outcome with a shorter treatment 
duration of adjuvant trastuzumab in patients with HER2+/ER-neg disease, but this 
comparison was non-significant in patients with HER2+/ER+ tumors. Moreover, in the 
PERSEPHONE trial (the only trial so far proving its non-inferiority hypothesis of 6 months 
vs. 1 year of trastuzumab), the HR for the comparison of the two strategies was very close to 
1 in the HER2+/ER+ subgroup (HR 0.91; 95% confidence interval, 0.68–1.21) (47). 
Therefore, in patients with HER2+/ER+ tumors, a shorter duration of trastuzumab treatment 
may be seen as a safe option by some – nonetheless, due to the late relapse profile of these 
tumors, longer follow-up data are needed before adopting this strategy.
The APT trial (in which patients with ≤3 cm, node-negative tumors received 12 weeks of 
paclitaxel and 1 year of trastuzumab) showed a 7-year invasive-DFS of 94.6% for 
HER2+/ER+ disease and of 90.7% for HER2+/ER-neg disease, with just four distant 
recurrences (1%) (48). Thus, this treatment de-escalation seems very safe for patients with 
low-burden tumors. Given the high chemo-sensitivity of HER2+/ER-neg tumors, leading to 
a higher rate of pCR, a possible strategy for avoiding anthracyclines in patients with 
somewhat larger tumors would be to assess the tumor’s sensitivity upfront with neoadjuvant 
double HER2-blockade plus a taxane. The DeCrescendo trial will test this hypothesis in 
patients with cT1c-T2N0 HER2+/ER-neg tumors, who will receive 12 weeks of taxanes plus 
trastuzumab/pertuzumab. Those who achieve pCR will be spared from adjuvant 
anthracyclines and will only receive double HER2-blockade until completion of 1 year of 
treatment. The study is powered to test 3-year relapse-free survival (RFS) rate, with a narrow 
confidence interval, primarily in patients with PAM50 HER2-Enriched tumors and then in 
the overall population.
The reduced chemo-sensitivity of HER2+/ER+ EBC fuels the interest in alternative, targeted 
approaches without chemotherapy. One is the use of CDK4/6 inhibitors, which synergize 
with trastuzumab in HER2+/ER+ tumor models (49). In the small NA-PHER2 study, 20 
weeks of palbociclib/ET/trastuzumab/pertuzumab provided a significant reduction in tumor 
proliferation, but led to a modest pCR rate of 27% (50). Long-term survival results and 
efficacy according to molecular subtypes are awaited. There are ongoing trials (PALTAN 
[NCT02907918]; TOUCH [NCT03644186]) exploring this approach. In particular, TOUCH 
is assessing RBsig (39) as a potential biomarker to identify HER2+/ER+ patients who could 
be spared from chemotherapy and treated with ET/anti-HER2/palbociclib. On the other 
hand, a recent joint analysis of neoadjuvant “chemotherapy-free” trials (SOLTI-PAMELA, 
TBCRC023/TBCRC006, and PerELISA) has shown that the combination of the HER2-
Enriched subtype with a high mRNA expression of ERBB2 leads to the identification of a 
subgroup of patients exquisitely sensitive to double HER2-blockade – with pCR rates 
ranging from 44.5%−66.7% (51). Among HER2+/ER+ patients, only 32% were “HER2-
Enriched/ERBB2-high”, whereas among the HER2+/ER-neg subgroup there were 68% of 
patients with this profile. Hence, as the HER2+/ER-neg subgroup is clearly enriched with 
these HER2-addicted tumors, one could envision a trial restricted to HER2+/ER-neg 
patients: they would be screened upfront and those with a HER2-enriched/ERBB2-high 
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expression tumor would be proposed to receive neoadjuvant trastuzumab/pertuzumab only. 
Like in the DeCrescendo trial, patients achieving pCR would be spared of any adjuvant 
chemotherapy and the primary endpoint would be a high RFS rate with a narrow confidence 
interval.
Conclusion
Given the predictive value of ER status, it would be reasonable for the next wave of clinical 
trials to target separately HER2+/ER+ and HER2+/ER-neg patients. This would lead to a 
better tailoring of de-escalation treatment strategies, and hence to a greater chance of 
“success”. In addition, this could greatly reduce the morbidity and costs associated with the 
long and intense systemic regimens that patients with HER2+ tumors still receive, despite 
years of biomarker research. Thus, besides the use of ER status, we feel that an integrated 
classification of HER2+ tumors, based on their DNA, RNA, protein expression and immune 
microenvironment would also be useful for further treatment refinement in the future.
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Statement of translational relevance
HER2+ early breast cancer is a heterogeneous disease, in which estrogen receptor (ER) 
status is emerging as a robust predictive marker. This is related to the fact that the ER- 
and HER2-pathways drive breast cancer proliferation by a complex interaction of cellular 
signaling processes, including the sharing of intracellular effectors such as MAPK, PI3K 
and Src3. Thus, due to the crosstalk between HER2 and ER, treatments targeting one 
pathway can induce the activation of the other. This leads to a different clinical behavior 
of HER2+/ER+ disease as compared to HER2+/ER-neg early breast cancer. We discuss 
how the timing and sequencing of treatments, including anti-HER2 targeted therapy, can 
influence their benefit according to ER status. We also propose different de-escalation 
trial designs, with potential impact on clinical practice, separately for HER2+/ER+ and 
HER2+/ER-neg breast cancer, which should be regarded as distinctly different.
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Figure 1 –. Current and future classification of HER2+ disease.
Legend: HER2+ tumors can be divided between estrogen receptor (ER)-positive and ER-
negative subgroups, according to the immunohistochemical expression of ER. Yet, at the 
molecular level, these tumors can be divided into the four molecular subtypes (luminal A, 
luminal B, HER2-enriched and basal-like), showing different molecular alterations, cell 
pathways activation and immune microenvironment. This leads to different responses to 
anti-HER2 treatment, as well to chemotherapy and endocrine therapy.
ER: estrogen receptor; HER2-E: HER2-enriched molecular subtype; LumA: luminal A 
molecular subtype; LumB: luminal B molecular subtype; mut: mutation; TILs: tumor-
infiltrating lymphocytes; WT: wild-type.
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Figure 2 –. Combining biomarkers in HER2+ disease.
Currently, protein expression assessed by immunohistochemistry is the standard method to 
classify breast cancer into different subtypes, according to tumor’s HER2 and estrogen 
receptors expression. However, an integrated classification of HER2-positive breast tumors, 
based on their DNA, RNA, protein expression, and microenvironment is needed to 
implement more precise and guided treatments and to identify those tumors “addicted” to 
the HER2 cellular pathway. Here, we propose a definition of “HER2-addicted” tumors that 
can be further refined in the future, as more data become available.
ER: estrogen receptor; HER2-E: HER2-enriched molecular subtype; PR: progesterone 
receptor; Rbsig: RB loss of function signature; WT: wild-type.
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